Multiple myeloma is a cancer of malignant plasma cells which stimulates osteoclasts and is associated with increased bone turnover and osteolysis. Bisphosphonates including zolendronic acid are used to prevent skeletal complications in patients with multiple myeloma. Orbital inflammation is a rare but serious complication following use of bisphosphonates. The diagnosis is made by excluding other possible causes in patients with myeloma and rapid initiation of therapy is required. Corticosteroids are the mainstay of therapy but the ideal treatment course has not been delineated. This report describes a case of this rare complication and provides a review of the literature.
Novartis. Zometa injection (package insert). East Hanover, NJ: Novartis, 2014.
2.
DrakeMTClarkeBLKhoslaS. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc2008; 83: 1032–1045.
3.
SkrepnekGHSealBTangiralaMet al.Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S.. Gen Dent2010; 58: 484–492.
4.
OlsonKVan PoznakC. Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Practice2007; 13: 223–229.
5.
KunzmannVBauerEFeurleJet al.Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood2000; 96: 384–392.
6.
FraunfelderFWFraunfelderJTJensvoldB. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol2003; 135: 219–222.
7.
BurkatCNVan BurenJJLucarelliMJ. Characteristics of orbital multiple myeloma: a case report and literature review. Surv Ophthalmol2009; 54: 697–704.
8.
ThuroBASavigOShinderRet al.Clinical presentation and anatomical location of orbital plasmacytomas. Ophthal Plast Reconstr Surg2018; 34: 258–261.
PhillipsPMNewmanSA. Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma. Arch Ophthalmol2008; 126: 137–139.
11.
SharmaNSOoiJMasselosKet al.Zoledronic acid infusion and orbital inflammatory disease. N Engl J Med2008; 359: 1410–1411.
12.
SethAAndersonDPAlbianiDAet al.Orbital inflammation and optic neuropathy with zoledronic acid for metastatic prostate cancer. Can J Ophthalmol2009; 44: 467–468.
13.
ProcianoyFProcianoyE. Orbital inflammatory disease secondary to single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis. Osteoporos Int2010; 21: 1057–1058.
14.
YangEBBirkholzESLeeAG. Another case of bisphosphonate-induced orbital inflammation. J Neuro-Ophthalmol2010; 30: 94–103.
15.
Ortiz-PerezSFernandezEMolinaJJet al.Two cases of drug-induced orbital inflammatory disease. Orbit2011; 30: 37–39.
16.
KaurHUyCKellyJet al.Orbital inflammatory disease in a patient treated with zoledronate. Endocr Pract2011; 17: e101–e103.
17.
PetersonJDBedrossianEH. Bisphosphonate-associated orbital inflammation—a case report and review. Orbit2012; 31: 119–123.
18.
RahimyELawSK. Orbital inflammation after zoledronate infusion: an emerging complication. Can J Ophthalmol2013; 48: e11–e12.
19.
BoniCKordicHChaloupkaK. Bisphosphonate-associated orbital inflammatory disease and uveitis anterior—a case report and review. Klin Monbl Augenheilkd2013; 230: 367–369.
20.
VoraMMRodgersIRUretskyS. Nitrogen bisphosphonate-induced orbital inflammatory disease: gamma delta T cells – a report and review of 2 cases. Ophthal Plast Reconstr Surg2014; 30: e84–e85.
21.
LefebvreDRMandevilleJTYonekawaYet al.A case series and review of bisphosphonate-associated orbital inflammation. Ocul Immunol Inflamm2016; 24: 134–139.
22.
PirbhaiARajakSHGooldLAet al.Bisphosphonate-induced orbital inflammation: a case series and review. Orbit2015; 34: 331–335.
23.
MuruganandamMSandhuH. Orbital inflammation secondary to zoledronic acid, a rare presentation. J Clin Rheumatol2016; 22: 384–384.
